STOCK TITAN

[Form 3] MANNKIND CORP Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Initial Form 3 filed for Ajay Ahuja reporting no beneficial ownership in MannKind Corp (MNKD). The filing lists Mr. Ahuja as Chief Medical Officer and a director/officer and notes the date of the triggering event as 09/29/2025. The form explicitly states No securities are beneficially owned and is signed on 10/09/2025. This is a routine Section 16 filing showing the officer currently holds no equity or derivative positions in the company.

Modulo Iniziale 3 presentato per Ajay Ahuja che riporta nessuna proprietà beneficiante in MannKind Corp (MNKD). Il modulo elenca il signor Ahuja come Chief Medical Officer e come direttore/ dirigente e annota la data dell'evento scatenante 09/29/2025. Il modulo specifica esplicitamente Nessuna titolarità di titoli è detenuta e viene firmato il 10/09/2025. Si tratta di un deposito di routine della Sezione 16 che mostra che l'ufficiale attualmente non detiene partecipazioni azionarie o posizioni derivate nella società.

Formulario Inicial 3 presentado por Ajay Ahuja que reporta no poseer propiedad beneficiosa en MannKind Corp (MNKD). El formulario enumera al señor Ahuja como Chief Medical Officer y como director/ejecutivo y señala la fecha del evento desencadenante como 09/29/2025. El formulario afirma explícitamente No se posee propiedad beneficiaria y se firma el 10/09/2025. Este es un trámite de rutina de la Sección 16 que demuestra que el funcionario actualmente no posee acciones ni posiciones derivadas en la empresa.

Ajay Ahuja에 대해 MannKind Corp (MNKD)에서 유익한 소유권이 없다고 보고된 Initial Form 3. 이 양식은 Ahuja 씨를 최고의료책임자(CMO) 겸 이사/임원으로 기재하고 촉발 사건 날짜를 09/29/2025로 명시합니다. 이 양식은 명시적으로 유익한 소유권이 없음이라고 표기되며 10/09/2025에 서명됩니다. 이는 현재 회사의 자본이나 파생상품 포지션을 보유하지 않는 임원이 있는 것을 보여주는 16조의 관례적인 제출 서류입니다.

Formulaire initial 3 déposé pour Ajay Ahuja indiquant qu'il n'a aucune propriété bénéficiaire dans MannKind Corp (MNKD). Le formulaire indique M. Ahuja comme Chief Medical Officer et en tant que directeur / dirigeant et indique la date de l'événement déclencheur comme 09/29/2025. Le formulaire affirme explicitement Aucune sécurité n'est détenue et est signé le 10/09/2025. Il s'agit d'un dépôt routinier de la Section 16 montrant que l'officier ne détient actuellement aucune action ou position dérivée dans la société.

Initial Form 3 file für Ajay Ahuja, der keinen wirtschaftlichen Eigentumsanteil an MannKind Corp (MNKD) meldet. Das Formular führt Herrn Ahuja als Chief Medical Officer und als Direktor/Beauftragter auf und vermerkt das Datum des auslösernden Ereignisses als 09/29/2025. Das Formular erklärt ausdrücklich Es bestehen keine Wertpapiere im wirtschaftlichen Eigentum und ist am 10/09/2025 unterschrieben. Dies ist eine routinemäßige Section-16-Einreichung, die zeigt, dass der leitende Angestellte derzeit kein Eigenkapital oder Derivatepositionen im Unternehmen hält.

النموذج الأولي 3 المقدم لـ Ajay Ahuja يذكر أنه لا يملك أي ملكية مستفيدة في MannKind Corp (MNKD). يسرد النموذج السيد Ahuja كـ Chief Medical Officer وكـ مدير/موظف مسير ويشير إلى تاريخ الحدث المحفز كـ 09/29/2025. ينص النموذج صراحةً لا توجد أوراق مالية مملوكة بشكل مفيد ويتم التوقيع في 10/09/2025. هذا إجراء روتيني لقسم 16 يُظهر أن المدير التنفيذي لا يملك حالياً أي أسهم أو مناصب مشتقة في الشركة.

初始表格3提交给Ajay Ahuja,报告在MannKind Corp(MNKD)中不具有受益所有权。 该表格将Ahuja先生列为首席医疗官(CMO)及董事/高管,并将触发事件日期标注为 09/29/2025。 表格明确声明 未拥有任何证券的受益所有权,并于 10/09/2025 签名。这是一个常规的第16条申报,显示该官员目前在公司不持有任何股权或衍生品头寸。

Positive
  • Full compliance with Section 16 initial reporting requirements
  • Clear disclosure that no securities are beneficially owned as of the event date
Negative
  • None.

Insights

Routine officer disclosure showing no current holdings.

The filing records Ajay Ahuja as Chief Medical Officer and a reporting director/officer for MannKind Corp (MNKD) with an event date of 09/29/2025 and a signed Form 3 dated 10/09/2025. The document explicitly states No securities are beneficially owned, meaning there are no listed common shares or derivative positions to report on initial ownership.

This is immaterial to MNKD's capital structure by itself but is relevant for insider trading monitoring and compliance; any future Form 4 or Form 5 filings would disclose subsequent purchases, grants, or dispositions and should be reviewed when filed.

Modulo Iniziale 3 presentato per Ajay Ahuja che riporta nessuna proprietà beneficiante in MannKind Corp (MNKD). Il modulo elenca il signor Ahuja come Chief Medical Officer e come direttore/ dirigente e annota la data dell'evento scatenante 09/29/2025. Il modulo specifica esplicitamente Nessuna titolarità di titoli è detenuta e viene firmato il 10/09/2025. Si tratta di un deposito di routine della Sezione 16 che mostra che l'ufficiale attualmente non detiene partecipazioni azionarie o posizioni derivate nella società.

Formulario Inicial 3 presentado por Ajay Ahuja que reporta no poseer propiedad beneficiosa en MannKind Corp (MNKD). El formulario enumera al señor Ahuja como Chief Medical Officer y como director/ejecutivo y señala la fecha del evento desencadenante como 09/29/2025. El formulario afirma explícitamente No se posee propiedad beneficiaria y se firma el 10/09/2025. Este es un trámite de rutina de la Sección 16 que demuestra que el funcionario actualmente no posee acciones ni posiciones derivadas en la empresa.

Ajay Ahuja에 대해 MannKind Corp (MNKD)에서 유익한 소유권이 없다고 보고된 Initial Form 3. 이 양식은 Ahuja 씨를 최고의료책임자(CMO) 겸 이사/임원으로 기재하고 촉발 사건 날짜를 09/29/2025로 명시합니다. 이 양식은 명시적으로 유익한 소유권이 없음이라고 표기되며 10/09/2025에 서명됩니다. 이는 현재 회사의 자본이나 파생상품 포지션을 보유하지 않는 임원이 있는 것을 보여주는 16조의 관례적인 제출 서류입니다.

Formulaire initial 3 déposé pour Ajay Ahuja indiquant qu'il n'a aucune propriété bénéficiaire dans MannKind Corp (MNKD). Le formulaire indique M. Ahuja comme Chief Medical Officer et en tant que directeur / dirigeant et indique la date de l'événement déclencheur comme 09/29/2025. Le formulaire affirme explicitement Aucune sécurité n'est détenue et est signé le 10/09/2025. Il s'agit d'un dépôt routinier de la Section 16 montrant que l'officier ne détient actuellement aucune action ou position dérivée dans la société.

Initial Form 3 file für Ajay Ahuja, der keinen wirtschaftlichen Eigentumsanteil an MannKind Corp (MNKD) meldet. Das Formular führt Herrn Ahuja als Chief Medical Officer und als Direktor/Beauftragter auf und vermerkt das Datum des auslösernden Ereignisses als 09/29/2025. Das Formular erklärt ausdrücklich Es bestehen keine Wertpapiere im wirtschaftlichen Eigentum und ist am 10/09/2025 unterschrieben. Dies ist eine routinemäßige Section-16-Einreichung, die zeigt, dass der leitende Angestellte derzeit kein Eigenkapital oder Derivatepositionen im Unternehmen hält.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Ahuja Ajay

(Last) (First) (Middle)
1 CASPER STREET

(Street)
DANBURY CT 06810

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/29/2025
3. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Ajay Ahuja 10/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the MNKD Form 3 filed by Ajay Ahuja report?

The Form 3 reports that Ajay Ahuja, listed as Chief Medical Officer and director/officer, does not beneficially own any securities of MannKind Corp as of 09/29/2025.

When was the MNKD Form 3 signed and when is the event date?

The event date on the filing is 09/29/2025 and the form bears a signature dated 10/09/2025.

Does this Form 3 show any stock options or derivatives for Ajay Ahuja?

No. The filing explicitly states No securities are beneficially owned, and no derivative securities or option holdings are listed.

Will future insider activity by Ajay Ahuja be reported?

Yes. Any future purchases, sales, or grants would be reported on subsequent Section 16 forms such as Form 4 (current reports) or Form 5 (annual reports).
Mannkind

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Latest SEC Filings

MNKD Stock Data

1.58B
301.53M
1.66%
55.86%
5.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
DANBURY